Thursday, October 12th, 2017 - TrialWire by Digital Mantra Group (DMG)

The effectiveness of a new investigational injectable therapy for blood sugar and weight control is now being assessed in an Australian clinical trial. www.diabetes2clinicaltrial.com

The clinical trial will look at how well the therapy can reduce blood sugar levels and body weight in people who are overweight and have Type 2 diabetes.

The investigational therapy and clinical trial medical check-ups are free of charge, and travel costs will be reimbursed.

The new investigational therapy, ZGN-1061, is designed for people who have Type 2 diabetes and are overweight - and are NOT yet on insulin.

To be eligible, participants also need to be overweight with a BMI of over 30, be able to visit their local participating medical clinic approximately 10 times over 5 months, and are aged from 18-65.

According to Diabetes Australia, one person every five minutes develops diabetes in Australia, and about 500,000 people have undiagnosed type 2 diabetes.

Diabetes is the leading cause of preventable blindness in Australia and there are more than 4,400 amputations every year as a result of diabetes.

“Diabetes is the epidemic of the 21st century and the biggest challenge confronting Australia’s health system.”

This medical study has been approved by the relevant health and medical authorities.

To find out more about this clinical trial please talk to your nurse or GP or find your nearest participating clinic here www.diabetes2clinicaltrial.com and discuss your condition with one of the medical team.

 

File Library

Contact Profile

Keywords

The effectiveness of a new investigational injectable therapy for blood sugar and weight control is now being assessed in an Australian clinical trial. www.diabetes2clinicaltrial.com? The clinical trial will look at how well the therapy can reduce blood

Categories

Sharing

More Formats